KRC-108

• Target:

  Trk receptor|||Others|||c-Met/HGFR|||Autophagy|||Apoptosis|||FLT

• Related Pathways:

  Autophagy|||Tyrosine Kinase/Adaptors|||Others|||Apoptosis|||Angiogenesis

• Bioactivity:

  KRC-108 is a multiple kinase inhibitor. KRC-108 is a potent inhibitor of Ron, Flt3 and TrkA as well as c-Met. KRC-108 inhibited oncogenic c-Met M1250T and Y1230D more strongly than wild type c-Met. The anti-proliferative activity of KRC-108 was measured by performing a cytotoxicity assay on a panel of cancer cell lines. The GI (50) values (i.e., 50% inhibition of cell growth) for KRC-108 ranged from 0.01 to 4.22 ?M for these cancer cell lines. KRC-108 was also effective for the inhibition of tumor growth in human HT29 colorectal cancer and NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice. This molecule should serve as a useful lead for inhibitors targeting kinases and may lead to new therapeutics for the treatment of cancer. (source: Invest New Drugs. 2012 Apr;30 (2) :518-23. doi: 10.1007/s10637-010-9584-2. Epub 2010 Nov 16.) .

• Smiles:

  NC1=C(C2=NC=3C(O2)=CC=CC3)C=C(C=N1)C4=CN(N=C4)C5CCNCC5

• Molecular Formula:

  C20H20N6O

• Molecular Weight:

  360.41

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  1146944-35-5